Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia

Table 1 Participant demographics and clinical characteristics

Variable	Total sample, N = 193, mean ± SD or number (%)
Age	74.9 ± 5.9
Female	102 (53%)
Education	16.7 ± 2.4
APOE ε4+	78 (40%)
Hispanic	18 (10%)
DRS	138.9 ± 4.3
MMSE	29.1 ± 1.3
CDR sum of boxes	0.3 ± 0.7
GDS	1.2 ± 1.7
Clinical Dx: normal	167 (87%)
Clinical Dx: MCI	26 (13%)
FSRP (%)	10.3 ± 7.9
Systolic BP	131.7 ± 18.6
Diastolic BP	80.4 ± 11.2
Pulse pressure	51.2 ± 13.9
PWV	8.9 ± 2.1
TIA	3 (2%)
Atrial fibrillation	20 (10%)
Diabetes	12 (6%)
CVD	27 (14%)
Smoking	4 (2%)
Antihypertensive medication use	94 (49%)
BMI	26.0 ± 5.6
N with CSF measures	123 (64%)
Interval from LP to PWV collection (years)	1.2 ± 0.9
Aβ₄₂	812.2 ± 378.6
Tau	358.8 ± 190.1
AD-like tau/Aβ₄₂ ratio	42 (34%)

Abbreviations: CN cognitively normal, MCI mild cognitive impairment, SD standard deviation, APOE apolipoprotein E, DRS Dementia Rating Scale, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating Scale, GDS Geriatric Depression Scale, FSRP Framingham Stroke Risk Profile, bp blood pressure. Pulse pressure was calculated as systolic blood pressure minus diastolic blood pressure. PWV pulse wave velocity, CVD cardiovascular disease, BMI body mass index, CSF cerebrospinal fluid, Tau total tau; AD Alzheimer’s disease, Aβ amyloid beta

ISSN: 1758-9193